4.8 Article

Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13

期刊

ELIFE
卷 7, 期 -, 页码 -

出版社

eLIFE SCIENCES PUBL LTD
DOI: 10.7554/eLife.39030

关键词

-

类别

资金

  1. National Cancer Institute NIH [R01 CA197336-02, R01 CA179483-02]
  2. U.S. Department of Defense [W81XWH-14-OCRP-OCACAOC140632]
  3. Cancer Prevention and Research Institute of Texas [RR150093]
  4. National Cancer Institute [R01CA215452-01]
  5. American Cancer Society Postdoctoral Fellowship [PF-17-010-01-CDD]

向作者/读者索取更多资源

High-grade serous ovarian cancer is characterized by extensive copy number alterations, among which the amplification of MYC oncogene occurs in nearly half of tumors. We demonstrate that ovarian cancer cells highly depend on MYC for maintaining their oncogenic growth, indicating MYC as a therapeutic target for this difficult-to-treat malignancy. However, targeting MYC directly has proven difficult. We screen small molecules targeting transcriptional and epigenetic regulation, and find that THZ1 - a chemical inhibiting CDK7, CDK12, and CDK13 - markedly downregulates MYC. Notably, abolishing MYC expression cannot be achieved by targeting CDK7 alone, but requires the combined inhibition of CDK7, CDK12, and CDK13. In 11 patient-derived xenografts models derived from heavily pre-treated ovarian cancer patients, administration of THZ1 induces significant tumor growth inhibition with concurrent abrogation of MYC expression. Our study indicates that targeting these transcriptional CDKs with agents such as THZ1 may be an effective approach for MYC-dependent ovarian malignancies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据